Literature DB >> 2538776

Reoperation for malignant astrocytoma.

N A Vick1, I S Ciric, T W Eller, J W Cozzens, A Walsh.   

Abstract

We evaluated 15 consecutive patients with malignant astrocytomas who were reoperated for functional status and survival. Their Karnovsky Performance Status (KPS) was not changed by surgery. None suffered perioperative death, wound infection, or complications. Patients with glioblastoma maintained KPS unchanged for a mean of 13 weeks (median, 10 weeks); with anaplastic astrocytoma, mean, 37.2 weeks (median, 24 weeks). Life spans were approximately twice that of non-reoperated historical controls. Reoperation for patients with recurrent malignant astrocytoma should be seriously considered when a gross total re-resection can be the goal in a patient whose tumor is in an accessible brain region.

Entities:  

Mesh:

Year:  1989        PMID: 2538776     DOI: 10.1212/wnl.39.3.430

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Should we reoperate for recurrent high-grade astrocytoma?

Authors:  Jin-fang Xu; Jun Fang; Yi Shen; Jian-min Zhang; Wei-guo Liu; Hong Shen
Journal:  J Neurooncol       Date:  2011-05-17       Impact factor: 4.130

2.  Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; D F Nelson; A J Fischbach; C H Chang; M Rotman; S O Asbell
Journal:  J Neurooncol       Date:  1992-03       Impact factor: 4.130

Review 3.  The role of cytoreductive surgery in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Authors:  Timothy Charles Ryken; Steven N Kalkanis; John M Buatti; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2014-04-23       Impact factor: 4.130

4.  Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme.

Authors:  David A Larson; Jeffrey M Suplica; Susan M Chang; Kathleen R Lamborn; Michael W McDermott; Penny K Sneed; Michael D Prados; William M Wara; M Kelly Nicholas; Mitchel S Berger
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

5.  Stereotactic brachytherapy using iodine 125 seeds for the treatment of primary and recurrent anaplastic glioma WHO° III.

Authors:  B Suchorska; C Hamisch; H Treuer; K Mahnkopf; R E Lehrke; M Kocher; M I Ruge; J Voges
Journal:  J Neurooncol       Date:  2016-07-15       Impact factor: 4.130

6.  Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.

Authors:  Florian Ringel; Haiko Pape; Michael Sabel; Dietmar Krex; Hans Christoph Bock; Martin Misch; Astrid Weyerbrock; Thomas Westermaier; Christian Senft; Philippe Schucht; Bernhard Meyer; Matthias Simon
Journal:  Neuro Oncol       Date:  2015-08-04       Impact factor: 12.300

7.  Safety and efficacy of concomitant chemotherapeutic wafers and iodine-125 seeds for recurrent glioblastoma.

Authors:  Andrew L Ko; Kathleen R Fink; Keith M Stelzer; Daniel L Silbergeld
Journal:  Surg Neurol Int       Date:  2012-11-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.